Search

Your search keyword '"P L, Bergsagel"' showing total 45 results

Search Constraints

Start Over You searched for: Author "P L, Bergsagel" Remove constraint Author: "P L, Bergsagel" Topic medicine Remove constraint Topic: medicine
45 results on '"P L, Bergsagel"'

Search Results

1. Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

2. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma

3. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

4. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

6. Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

7. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

8. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

9. Ploidy status rarely changes in myeloma patients at disease progression

10. Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

11. A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy

12. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature

13. Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

14. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

15. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain [published erratum appears in Blood 1995 Jun 1;85(11):3365]

16. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

17. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

18. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

19. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma

20. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

21. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma

22. Expression and mutation status of candidate kinases in multiple myeloma

23. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

24. Targeted sequencing of relapsed/refractory myeloma patients identifies an enrichment of mutations in MAPK and Cereblon pathways

25. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

26. Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation

27. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

28. Maintained rules of development in a mouse B-cell tumor

29. Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity

30. B350 SNS-032, a Potent and Selective CDK2, 7 and 9 Inhibitor, Demonstrates Preclinical Activity in Human Multiple Myeloma

31. Reply to the research mission in myeloma by Richardson et al

32. Erratum: Expression and mutation status of candidate kinases in multiple myeloma

33. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

34. Genes Expressed Selectively in Murine and Human Plasma Cell Neoplasms

35. The Blood B-Cells and Borie Marrow Plasma Cells in Patients with Multiple Myeloma Share Identical IgH Rearrangements

36. Generation of an automated tool for querying myeloma transcriptomics for multiple gene expression signatures used in risk-stratification

37. Genes Expressed Selectively in Plasmacytomas: Markers of Differentiation and Transformation

39. B557 Molecular Pathogenesis of MGUS and Multiple Myeloma

40. Impact of lenalidomide therapy on stem cell mobilization in myeloma

41. Efficacy of induction with cybord in newly diagnosed multiple myeloma

42. High-resolution assessment of chromosomal gains and losses in multiple myeloma tumors from bortezomib clinical trial

44. Identification of Consensus Genes Expressed in Plasmacytomas but Not B Lymphomas

45. Prediction of response to bortezomib and dexamethasone resistance in myeloma (MM) by novel mutations in the NFKB pathway

Catalog

Books, media, physical & digital resources